RPG Life Sciences Limited (RPGLIFE.BO)
INR 2039.75
(1.94%)
INR 2039.75
(1.94%)
| Year | Gross Profit | Gross Profit Growth |
|---|---|---|
| 2023 | 2.48 Billion INR | -24.95% |
| 2022 | 3.3 Billion INR | 15.3% |
| 2021 | 2.86 Billion INR | 16.77% |
| 2020 | 2.45 Billion INR | 4.81% |
| 2019 | 2.34 Billion INR | 9.63% |
| 2018 | 2.13 Billion INR | -3.89% |
| 2017 | 2.22 Billion INR | 20.12% |
| 2016 | 1.85 Billion INR | -1.18% |
| 2015 | 1.87 Billion INR | 19.31% |
| 2014 | 1.57 Billion INR | -1.05% |
| 2013 | 1.58 Billion INR | 9.37% |
| 2012 | 1.45 Billion INR | 5.58% |
| 2011 | 1.37 Billion INR | 0.31% |
| 2010 | 1.37 Billion INR | 20.99% |
| 2009 | 1.13 Billion INR | 15.38% |
| 2008 | 982.15 Million INR | 10.93% |
| 2007 | 885.4 Million INR | 13.0% |
| 2006 | 783.54 Million INR | 0.0% |
| Year | Gross Profit | Gross Profit Growth |
|---|---|---|
| 2024 Q1 | 723.8 Million INR | 47.77% |
| 2023 Q1 | 606 Million INR | -10.76% |
| 2023 Q2 | 1.08 Billion INR | 79.6% |
| 2023 FY | 2.48 Billion INR | -24.95% |
| 2023 Q4 | 489.8 Million INR | -53.59% |
| 2023 Q3 | 1.05 Billion INR | -3.04% |
| 2022 Q3 | 881.3 Million INR | -1.44% |
| 2022 Q4 | 679.1 Million INR | -22.94% |
| 2022 FY | 3.3 Billion INR | 15.3% |
| 2022 Q2 | 894.2 Million INR | 4.72% |
| 2022 Q1 | 853.9 Million INR | 51.94% |
| 2021 Q3 | 793.5 Million INR | 1.44% |
| 2021 FY | 2.86 Billion INR | 16.77% |
| 2021 Q4 | 562 Million INR | -29.17% |
| 2021 Q1 | 731.8 Million INR | 52.94% |
| 2021 Q2 | 782.2 Million INR | 6.89% |
| 2020 Q1 | 623.8 Million INR | 20.59% |
| 2020 FY | 2.45 Billion INR | 4.81% |
| 2020 Q4 | 478.5 Million INR | -31.02% |
| 2020 Q3 | 693.7 Million INR | 4.85% |
| 2020 Q2 | 661.6 Million INR | 6.06% |
| 2019 Q2 | 658.8 Million INR | 7.45% |
| 2019 FY | 2.34 Billion INR | 9.63% |
| 2019 Q1 | 613.1 Million INR | 55.93% |
| 2019 Q4 | 517.3 Million INR | -17.19% |
| 2019 Q3 | 624.7 Million INR | -5.18% |
| 2018 Q4 | 393.2 Million INR | -36.27% |
| 2018 FY | 2.13 Billion INR | -3.89% |
| 2018 Q3 | 617 Million INR | 6.88% |
| 2018 Q2 | 577.3 Million INR | 4.72% |
| 2018 Q1 | 551.3 Million INR | -1.5% |
| 2017 FY | 2.22 Billion INR | 20.12% |
| 2017 Q4 | 559.7 Million INR | -10.19% |
| 2017 Q3 | 623.2 Million INR | 6.38% |
| 2017 Q2 | 585.8 Million INR | 11.64% |
| 2017 Q1 | 524.7 Million INR | 11.4% |
| 2016 Q1 | 502 Million INR | 7.98% |
| 2016 FY | 1.85 Billion INR | -1.18% |
| 2016 Q3 | 442.6 Million INR | -9.3% |
| 2016 Q2 | 488 Million INR | -2.79% |
| 2016 Q4 | 471 Million INR | 6.42% |
| 2015 Q2 | 447.6 Million INR | 4.78% |
| 2015 Q1 | 427.2 Million INR | -6.81% |
| 2015 FY | 1.87 Billion INR | 19.31% |
| 2015 Q3 | 492.4 Million INR | 10.01% |
| 2015 Q4 | 464.9 Million INR | -5.58% |
| 2014 Q4 | 458.4 Million INR | 17.66% |
| 2014 FY | 1.57 Billion INR | -1.05% |
| 2014 Q1 | 368.3 Million INR | 7.25% |
| 2014 Q2 | 361.9 Million INR | -1.74% |
| 2014 Q3 | 389.6 Million INR | 7.65% |
| 2013 Q2 | 427.1 Million INR | -3.13% |
| 2013 FY | 1.58 Billion INR | 9.37% |
| 2013 Q4 | 343.4 Million INR | -8.28% |
| 2013 Q3 | 374.4 Million INR | -12.34% |
| 2013 Q1 | 440.9 Million INR | 7.98% |
| 2012 FY | 1.45 Billion INR | 5.58% |
| 2012 Q2 | 384.6 Million INR | 4.37% |
| 2012 Q1 | 368.5 Million INR | 0.0% |
| 2012 Q4 | 408.3 Million INR | 32.74% |
| 2012 Q3 | 307.6 Million INR | -20.02% |
| 2011 FY | 1.37 Billion INR | 0.31% |
| 2010 FY | 1.37 Billion INR | 20.99% |
| 2009 FY | 1.13 Billion INR | 15.38% |
| 2008 FY | 982.15 Million INR | 10.93% |
| 2007 FY | 885.4 Million INR | 13.0% |
| 2006 FY | 783.54 Million INR | 0.0% |
| Name | Gross Profit | Gross Profit Difference |
|---|---|---|
| Alembic Pharmaceuticals Limited | 26.78 Billion INR | 90.728% |
| Aurobindo Pharma Limited | 154.68 Billion INR | 98.395% |
| Glenmark Life Sciences Limited | 12.43 Billion INR | 80.029% |
| Granules India Limited | 16.79 Billion INR | 85.22% |
| Indoco Remedies Limited | 6.04 Billion INR | 58.9% |
| Achyut Healthcare Limited | 4.86 Million INR | -50980.025% |
| Ajanta Pharma Limited | 21.06 Billion INR | 88.212% |
| Alkem Laboratories Limited | 52.29 Billion INR | 95.252% |
| Alpa Laboratories Limited | 188.89 Million INR | -1214.487% |
| Brooks Laboratories Limited | 65.62 Million INR | -3683.907% |
| AstraZeneca Pharma India Limited | 6.22 Billion INR | 60.098% |
| Bajaj HealthCare Limited | 1.47 Billion INR | -68.704% |
| Bliss GVS Pharma Limited | 3.69 Billion INR | 32.809% |
| Dr. Reddy's Laboratories Limited | 163.6 Billion INR | 98.482% |
| Eris Lifesciences Limited | 10.42 Billion INR | 76.186% |
| FDC Limited | 8.33 Billion INR | 70.209% |
| Glenmark Pharmaceuticals Limited | 69.34 Billion INR | 96.419% |
| Gufic Biosciences Limited | 4.16 Billion INR | 40.423% |
| Ind-Swift Laboratories Limited | 6.19 Billion INR | 59.915% |
| Ipca Laboratories Limited | 29.8 Billion INR | 91.671% |
| Jagsonpal Pharmaceuticals Limited | 652.59 Million INR | -280.484% |
| Krebs Biochemicals & Industries Limited | 192.72 Million INR | -1188.351% |
| Lasa Supergenerics Limited | 121.02 Million INR | -1951.557% |
| Laurus Labs Limited | 24.62 Billion INR | 89.915% |
| Lupin Limited | 123.71 Billion INR | 97.993% |
| Mankind Pharma Limited | 44.52 Billion INR | 94.423% |
| Medicamen Biotech Limited | 495.49 Million INR | -401.115% |
| Medico Remedies Limited | 262.14 Million INR | -847.189% |
| Megasoft Limited | 342.07 Million INR | -625.873% |
| NATCO Pharma Limited | 25.73 Billion INR | 90.352% |
| Piramal Pharma Limited | 24.47 Billion INR | 89.853% |
| Sigachi Industries Limited | 2 Billion INR | -24.008% |
| Sun Pharmaceutical Industries Limited | 258.48 Billion INR | 99.039% |
| Suven Pharmaceuticals Limited | 4.12 Billion INR | 39.781% |
| Syncom Formulations (India) Limited | 942.39 Million INR | -163.477% |
| Unichem Laboratories Limited | 4.86 Billion INR | 48.961% |
| Wanbury Limited | 1.73 Billion INR | -43.473% |
| Windlas Biotech Limited | 1.33 Billion INR | -85.465% |
| ZIM Laboratories Limited | 1.26 Billion INR | -95.992% |
| Zydus Lifesciences Limited | 125.21 Billion INR | 98.017% |
| Sun Pharma Advanced Research Company Limited | -602.4 Million INR | 512.18% |
| Divi's Laboratories Limited | 32.44 Billion INR | 92.346% |
| Hester Biosciences Limited | 1.27 Billion INR | -94.952% |
| Procter & Gamble Health Limited | 5.78 Billion INR | 57.052% |
| Amrutanjan Health Care Limited | 1.55 Billion INR | -59.521% |
| Bal Pharma Limited | 770.19 Million INR | -222.386% |
| Strides Pharma Science Limited | 14.38 Billion INR | 82.743% |
| Venus Remedies Limited | 2.18 Billion INR | -13.764% |
| Aarti Pharmalabs Limited | 5.83 Billion INR | 57.42% |
| Nectar Lifesciences Limited | 2.97 Billion INR | 16.455% |
| Shilpa Medicare Limited | 3.54 Billion INR | 29.994% |
| Aarti Drugs Limited | 8.31 Billion INR | 70.143% |
| IOL Chemicals and Pharmaceuticals Limited | 4.58 Billion INR | 45.795% |
| Suven Life Sciences Limited | -200.79 Million INR | 1336.572% |
| Ind-Swift Limited | 2.17 Billion INR | -14.291% |
| Valiant Laboratories Limited | -60.66 Million INR | 4193.037% |
| J. B. Chemicals & Pharmaceuticals Limited | 22.69 Billion INR | 89.062% |
| Solara Active Pharma Sciences Limited | 861.2 Million INR | -188.319% |
| Themis Medicare Limited | 1.5 Billion INR | -65.104% |
| Hikal Limited | 3.14 Billion INR | 21.001% |
| Torrent Pharmaceuticals Limited | 46.75 Billion INR | 94.69% |
| Sequent Scientific Limited | 2.97 Billion INR | 16.642% |
| Novartis India Limited | 1.32 Billion INR | -87.128% |
| Wockhardt Limited | 16.24 Billion INR | 84.711% |
| Jubilant Pharmova Limited | 19.64 Billion INR | 87.359% |
| Biofil Chemicals and Pharmaceuticals Limited | 14.57 Million INR | -16930.529% |
| Neuland Laboratories Limited | 8.24 Billion INR | 69.895% |
| Morepen Laboratories Limited | 6.16 Billion INR | 59.7% |
| Kilitch Drugs (India) Limited | 620.47 Million INR | -300.176% |
| Mangalam Drugs & Organics Limited | 703.6 Million INR | -252.897% |